# Amalgam RX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amalgam-rx

- Industry: Healthcare IT
- Headquarters: Wilmington, US
- Website: www.amalgamrx.com/
- Latest round: Series B (Oct 5, 2023)
- Investors on record: 1

## About

Amalgam RX, Inc., based in the US, specializes in integrated point-of-care solutions that optimize clinical workflows within Electronic Health Records (EHR) systems, enhancing patient outcomes and engagement through its innovative technology. Founded in 2016, Amalgam RX, Inc. operates from Wilmington, US, providing digital health solutions to healthcare providers, life sciences companies, and health plans. In August 2025, Amalgam RX, Inc. raised USD 12 million in venture funding from Catalio Capital Management. The round was part of a larger USD 20 million venture debt funding. The current company valuation stands at USD 214.417 mn. The CEO of Amalgam RX is Ryan Sysko, who has a background in healthcare technology and entrepreneurship. Amalgam RX specializes in integrated point-of-care solutions designed to enhance clinical workflows within Electronic Health Records (EHR) systems. Their offerings include patient identification tools, clinical trial recruitment applications, care guidelines, and financial assistance mechanisms, all aimed at improving patient outcomes and engagement. Built on a configurable, AI-powered platform, these digital health solutions support medication adherence, patient education, and device integration, ultimately striving to optimize treatment regimens and improve quality of life. Amalgam RX markets its solutions across North America, Europe, Asia, and Australia.Amalgam RX generates revenue primarily through partnerships with life sciences companies, health plans, and providers, focusing on the commercialization of digital therapeutic interventions and regulated Software as a Medical Device (SaMD). Their transactions involve B2B collaborations, integrating Amalgam's solutions into existing clinical workflows, benefiting from advanced AI capabilities and clinical validation. The company's approach emphasizes the development of customized applications based on validated modules, aligning closely with the stringent demands of the healthcare sector. The company will use the August 2025 funding to accelerate its market expansion and refinance its corporate debt.

## Funding rounds

- Series B, Oct 5, 2023 — CVS Health Ventures

## Investors

- CVS Health Ventures (https://capitalatlas.ai/funds/cvs-health-ventures) — Series B